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ABSTRACT
Objective: To provide preliminary evidence for the
impact of problem-solving therapy for diabetes
(PST-D) in adults with diabetic retinopathy (DR) and
diabetes distress.
Research design and methods: In a pilot
randomized controlled trial, 40 participants with DR
and diabetes distress were allocated to the PST-D or
control groups. Diabetes distress (DDS), depressive
symptoms (PHQ-9), self-care activities (SDSCA), and
HbA1c were assessed at baseline, and 3 and 6-month
follow-ups.
Results: At the 6-month follow-up, the PST-D group
showed significant improvements relative to the control
group, in ‘regimen-related distress’ (PST-D: −1.3±1.4;
control: −0.4±1.1), depressive symptoms (PST-D:
−4.3±6.1; control: −0.3±4.6), and HbA1c (PST-D:
−1.2%±1.01; control: 0.2%±1.2%) (all p<0.05). In
multiple regression analysis, adjusting for baseline
values and sociodemographic factors, PST-D was
associated with significant improvement in ‘regimen-
related distress’, depressive symptoms, and HbA1c at
the 6-month follow-up (p<0.05).
Conclusions: PST-D is a promising intervention for
improving psychological outcomes and glycemic
control. A fully powered study is required to confirm
these findings and examine mechanisms of change in
HbA1c.
Trial registration number: ACTRN12616001010482;
results.
INTRODUCTION
There is overwhelming evidence that dia-
betes distress and depressive symptoms are
common in people with diabetes and have
detrimental implications for quality of life,
family functioning, diabetes outcomes, and
healthcare costs.1 Rates of depression are
higher in those with complications of dia-
betes2 and prospective studies have identiﬁed
that depression is a risk factor for the pro-
gression of diabetic microvascular complica-
tions.3 For example, depressive symptoms
were related to a threefold increased risk of
progression from non-proliferative diabetic
retinopathy (NPDR) to proliferative DR
(PDR) in a 6-year period.3
Recent reviews and meta-analyses of depres-
sion interventions in diabetes have found few
studies that have shown simultaneous
improvement in psychological outcomes and
HbA1c.
4 This may be because depression treat-
ments are often delivered in isolation from
diabetes care. An integrated approach that
focuses on depressive symptoms and diabetes
distress in the context of diabetes manage-
ment is likely to be more effective. Indeed,
Significance of this study
What is already known about this subject?
▪ We know that diabetes distress and depressive
symptoms are common in people with diabetes
and have a huge impact on many aspects of life.
▪ Evidence-based low-intensity psychological treat-
ments exist but are not targeted or easily avail-
able within diabetes services.
What are the new findings
▪ This study provides preliminary evidence that
problem-solving therapy tailored to diabetes can
improve diabetes distress, depressive symptoms,
and HbA1c in people with diabetic retinopathy
who are distressed by diabetes.
How might these results change the focus
of research or clinical practice?
▪ These findings highlight an approach that could
be delivered by staff in the diabetes or primary
care team allowing full integration into existing
services.
▪ Further research is needed to examine the causal
mechanisms underlying change in HbA1c and
determine the longer term impact on psycho-
logical and clinical outcomes.
▪ Practical issues regarding implementation of
problem-solving therapy tailored to diabetes as
an integrated component of diabetes services
require investigation.
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diabetes distress is more common than depression in
people with diabetes, and more closely associated with
diabetes self-management and glycemic control.5 6 This
has led to the hypothesis that psychological interventions,
which speciﬁcally address diabetes and are integrated in
diabetes care, could improve psychological and biomed-
ical outcomes in those with high levels of diabetes dis-
tress.5 6 Evidence from a large trial of stepped care for
depression in people with diabetes suggests that the
greatest gains were obtained by those people presenting
with micro and macrovascular complications.7 To date
though, few studies have speciﬁcally focused on diabetes
distress,8 and no study has targeted psychological inter-
ventions tailored for people with DR. The implications
are clear: interventions that target the distress associated
with diabetes as well as general depressive symptoms are
likely to be most effective in improving mental health
and clinical outcomes. However, this is yet to be tested
empirically in those with the highest rates of depressive
symptoms, that is, people with microvascular complica-
tions. To address this need, we recently adapted an
evidence-based treatment for depression, namely
‘problem-solving therapy for primary care’ (PST-PC),9 to
target diabetes-related problems that cause distress in
people with DR. We chose to adapt PST-PC because it
can be delivered by clinicians without speciﬁc mental
health qualiﬁcations, enabling us to deliver the interven-
tion via health professionals such as diabetes educators,
eye care health professionals, or other allied health pro-
fessionals responsible for the care of individuals with dia-
betes and DR. We tailored PST-PC to focus on
problem-solving skill development to address speciﬁc bar-
riers to diabetes management and aspects of diabetes
and its complications that cause distress. Therefore, our
approach enabled participants to identify and address
challenges they experience in living with, and managing
diabetes, as well as achieve the generic problem-solving
skills and behavioral activation that reduces depression.
We hypothesized that this intervention would reduce
diabetes distress and depressive symptoms; and improve
diabetes self-care and HbA1c. We chose to focus on dia-
betes distress as our primary outcome (and inclusion cri-
terion) rather than heightened depressive symptoms,
since diabetes distress is more common and maybe more
amenable to change through interventions that can be
delivered in non-mental health setting.8 However, given
that our intervention was an adaptation of an evidence-
based intervention for depression, depressive symptoms
were investigated as a secondary outcome measure. The
aim of this pilot study was to establish preliminary evi-
dence for the efﬁcacy of diabetes-speciﬁc PST (PST-D).
RESEARCH DESIGN AND METHODS
Recruitment and eligibility
Forty participants were recruited from retinal clinics at
the Royal Victoria Eye and Ear Hospital (RVEEH),
Melbourne, Australia. A sample size of 40 was chosen
for pragmatic reasons to be a feasible recruitment target
for a pilot study. Inclusion criteria were (1) diagnosis of
type 2 diabetes; (2) conﬁrmed diagnosis of DR; (3) at
least moderate diabetes-speciﬁc distress on the Diabetes
Distress Scale (DDS) (overall score ≥2.0),10 (4) at least
18 years old. Exclusion criteria were (1) insufﬁcient
English language skills to engage in PST-D sessions and
the research interviews as determined by the research
assistant; (2) insufﬁcient cognitive ability to engage in
PST-D as indicated by the 6-item Cognitive Impairment
Test.11
Medical ﬁles were screened and individuals who could
be identiﬁed as having type 2 diabetes and DR were
approached at the clinic or called by telephone to
discuss the study. All potential participants were pro-
vided with a plain language statement and provided
written consent to participate in the project. Ethics
approval was obtained from the Royal Victorian Eye and
Ear Hospital’s Human Research Ethics Committee
(HREC; project number 08/815H). Potential partici-
pants were invited to attend an appointment in which
eligibility criteria were assessed and a retinal image of
each eye obtained for grading to conﬁrm DR diagnosis.
Those individuals who met the study eligibility criteria
completed a baseline assessment.
Data collection
Retinal photographs were obtained from two-ﬁeld
fundus photographs (Canon CR6—45NM, Canon,
Japan) and clinical signs of DR graded following the
modiﬁed Airlie House classiﬁcation system.12
All assessments were conducted by a research assistant
blinded to allocation. At baseline, clinical assessments
included HbA1c collected by venepuncture and analyzed
via a pathology service and presenting visual acuity using
a 3 m logarithm of the minimum angle of resolution
chart (LogMAR). Diabetes duration, medications, and
sociodemographic details were assessed by self-report.
Structured interviews were conducted at baseline, and
then again 3 and 6 months later (1) 17-item diabetes-
speciﬁc distress (DDS13) which provides a total score
and four subscales: ‘physician-related distress’, ‘regimen-
related distress’, ‘diabetes-related interpersonal distress’,
and ‘emotional burden’; (2) depressive symptoms
(9-item Patient Health Questionnaire (PHQ-9)14); and
(3) diabetes self-care behaviors (revised version of the
Summary of Diabetes Self-Care Activities (SDSCA)15)
which provides an overview of speciﬁc diabetes self-
management activities in the last 7 days (eg, general
diet, speciﬁc diet, exercise, smoking, and blood glucose
testing). HbA1c was also assessed at all visits.
Randomization and intervention groups
After the baseline interview, all participants in both
groups were provided with publically available informa-
tion brochures on diabetes-speciﬁc topics produced by
Diabetes Victoria (ie, Living well with type 2 diabetes,
Managing stress and diabetes, Diabetes and the eyes,
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and Monitoring blood glucose levels). Following base-
line assessment, participants were randomized to the
PST-D intervention (n=21) or control (n=19) group
using a computer-generated random number sequence,
generated and concealed using sealed envelopes by a
clinical trials expert (external to the study team). The
control group received care as usual.
We adapted the PST manual so that participants
focused on problems speciﬁcally related to their dia-
betes and DR. The PST-D intervention consisted of up
to eight sessions, each lasting 45–60 min, and delivered
via telephone or in person (depending on participant’s
availability and preference) by a research assistant
trained in PST-D delivery, under the supervision of a
clinical psychologist (BS). During the ﬁrst session, the
participant was introduced to PST-D, and the rationale
explained in the context of diabetes, complications, and
distress. The interventionist then worked with the par-
ticipant to identify problems related speciﬁcally to dia-
betes and its complications. This was facilitated initially
by discussing participants’ responses on the DDS and
subsequently the development of a problem list related
to diabetes across all domains of life. In all sessions, the
participant chose a speciﬁc diabetes-related problem to
work on and was guided through the problem-solving
steps: (a) clarifying and deﬁning the problem; (b)
setting a realistic goal; (c) brainstorming multiple solu-
tion alternatives; (d) evaluating each solution for its
advantages and obstacles to implementation; (e) choos-
ing a preferred solution; (f) devising a speciﬁc action
plan to implement the solution; and (g) evaluating out-
comes from the previous session (sessions 2–8). Also,
each session included activity scheduling, whereby parti-
cipants make speciﬁc plans to engage in enjoyable
activities, which are concordant with optimizing diabetes
management during the following week. Sessions all fol-
lowed the same structure with the interventionist
working toward ensuring that the participant was taking
a more active role in leading the problem-solving
process as sessions progressed.
Statistical analyses
Univariate analysis assessed for group differences
between participant characteristics at baseline and
changes in outcome measures at 3 and 6 months.
Controlling for confounders (baseline values, age,
gender, duration of diabetes, diabetes medication, visual
acuity), multiple regression analyses were used to assess
the impact of PST-D on outcome variables at 3 and
6-month follow-up. Post hoc power estimations were con-
ducted to determine the power to detect an intervention
effect, and based on our 6-month follow-up with PST
intervention and six covariates noted above in the mul-
tiple linear regression analysis. We estimated the power
based on the changes in the adjusted R2 when the inter-
vention is included in the model. For PHQ-9, the R2 is
48.01% for the full model (including the intervention
group) and 39.00% for the reduced model (excluding
the intervention group). The R2 change is 0.09, with a
sample size of 34 and a signiﬁcance level of 0.05, we had
45.30 power to detect the difference between the PST
intervention and usual care group. The power to detect
an intervention effect on HbA1c and DDS was 92% and
12%, respectively.
Univariate analysis assessed for group differences at
baseline between participants in the intervention group
who completed follow-up assessments and those who
were lost to follow-up.
RESULTS
The mean age of participants was 59.9±7.8 years and
67.5% (n=27) were men. The average duration of type 2
diabetes was 21.0±16.0 years, and HbA1c was 8.2±1.6%
(65.6 mmol/mol). At baseline, the PST-D and control
groups were comparable in terms of sociodemographic
and clinical characteristics, as well depressive symptoms
and diabetes distress scores, except for the DDS
‘diabetes-related interpersonal distress’ subscale which
was signiﬁcantly higher in the PST-D group than the
control group (PST-D: 3.0±1.2; control: 2.5±1.2, p=0.009)
(table 1).
Two participants declined further PST-D after one
session. One participant received only four PST-D ses-
sions due to illness. The remaining 18 participants
received between 5 and 8 sessions. Six participants in
the PST-D group did not attend the ﬁnal follow-up, with
an additional two declining the ﬁnal HbA1c assessment.
All control group participants attended the follow-up
assessments; although at each follow-up, HbA1c was not
obtained from one participant. Compared with partici-
pants in the intervention group who completed the
study, those who were lost to follow-up assessments had
lower scores on the DDS ‘regimen-related distress’ sub-
scale at baseline (PST-D completers: 3.4±1.4; PST-D lost
to follow-up: 2.1±0.9; p=0.04). There was also a trend to
suggest that those lost to follow-up were more likely to
be living alone (60%) than those who completed all
follow-up assessments (13.3%; p=0.07). No other differ-
ences were observed.
At 3 months, there was a non-signiﬁcant trend, sug-
gesting a slightly greater reduction in ‘regimen-related
distress’ in the PST-D group (−1.2±1.2) relative to the
control group (−0.4±1.4; p=.08). At the 6-month
follow-up, the between-group difference in change
scores reached statistical signiﬁcance (PST-D: −1.3±1.4;
control: −0.4±1.1; p=0.03). Compared with the control
group, the PST-D group also showed a signiﬁcantly
greater reduction at 3 months in ‘diabetes-related inter-
personal distress’ relative to the control group which
demonstrated an increase (PST-D: −0.9±1.4; control: 0.2
±1.1; p=0.01). Depressive symptoms reduced signiﬁcantly
more so in the intervention compared with control
group at 3-month follow-up (PST-D: −3.8±3.0; control:
−1.1±3.9; p=0.03). This latter difference was higher at 6
months with the PST-D group showing a −4.3±6.1
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Table 1 Participants’ characteristics at baseline and 3 and 6-month primary and secondary outcomes
Characteristics Total sample (n=40) PST-D (n=21) Control group (n=19) p Value
Categorical variables n (%)
Gender (male) 27 (67.5) 14 (66.7) 13 (68.4) 0.906
Education (>high school) 21 (50.0) 11 (52.4) 9 (47.4) 0.752
Living alone (yes) 8 (20.5) 5 (25.0) 3 (15.8) 0.476
Continuous variables Mean (SD)
Age (years) 59.9 (7.8) 60.1 (7.0) 59.6 (8.8) 0.839
Duration of diabetes (years)* 21.0 (16.0) 17.5 (10.0) 23.0 (15.0) 0.190
Worse eye best presenting distance visual acuity (logMAR)* 0.2 (0.3) 0.2 (0.2) 0.2 (0.4) 0.923
Baseline 3-month follow-up 6-month follow-up
Outcome Measures Total Sample (n=40) PST-D (n=21) Control (n=19) p Value PST-D (n=16)
Control
(n=19) p Value PST-D (n=16) Control (n=19)
p
Value
DDS: total score 2.8 (0.7) 2.9 (0.8) 2.7 (0.6) 0.734 2.2 (1.1) 2.5 (0.9) 0.457 2.2 (1.1) 2.5 (0.8) 0.427
DDS: emotional burden 3.6 (0.9) 3.6 (0.9) 3.7 (1.0) 0.734 2.8 (1.2) 3.3 (1.4) 0.248 2.8 (1.3) 3.2 (1.6) 0.372
DDS: physician-related
distress
1.0 (1.0) 1.9 (1.1) 1.8 (1.0) 0.679 1.9 (1.3) 1.7 (1.1) 0.542 1.6 (1.3) 176 (0.6) 0.768
DDS: regimen-related
distress
3.0 (1.2) 3.0 (1.4) 3.0 (1.0) 0.834 2.1 (1.2) 2.5 (1.0) 0.236 2.1 (1.1) 2.6 (0.9) 0.175
DDS: diabetes-related
interpersonal distress
2.5 (1.2) 3.0 (1.2) 2.0 (0.9) 0.009 2.0 (1.4) 2.2 (0.9) 0.658 2.3 (1.3) 2.1 (1.0) 0.674
HbA1c %, mmol/mol 8.2% (1.57) 66.1 mmol/mol 8.1 (1.2) 65.0 mmol/mol 8.2 (2.0)
66.1 mmol/mol
0.964 7.6 (0.9)
59.6 mmol/mol
8.3 (2.1)
67.2 mmol/
mol
0.295 7.1 (1.1) 54.1 mmol/mol 8.4 (2.5) 68.3 mmol/mol 0.093
PHQ-9: depressive
symptoms
10.4 (5.4) 10.5 (5.2) 10.2 (5.7) 0.832 7.1 (5.9) 9.1 (7.0) 0.364 6.7 (5.9) 9.9 (6.5) 0.144
SDSCA: general diet 5.2 (0.3) 5.5 (1.7) 4.9 (1.8) 0.321 5.2 (1.8) 4.8 (2.0) 0.546 6.1 (1.1) 5.0 (1.5) 0.026
SDSCA: specific diet 4.9 (1.5) 4.9 (1.2) 4.8 (1.5) 0.790 4.6 (1.7) 4.8 (1.5) 0.728 4.7 (1.3) 5.4 (1.4) 0.161
SDSCA: exercise 3.2 (0.3) 3.3 (2.3) 3.2 (2.1) 0.941 3.84 (2.31) 2.79 (2.13) 0.170 3.60 (2.69) 3.37 (2.11) 0.780
SDSCA: blood sugar
testing
5.4 (0.4) 5.3 (2.4) 5.5 (2.5) 0.855 5.94 (1.89) 5.53 (2.29) 0.571 5.97 (1.87) 5.13 (2.71) 0.317
Bold indicates significance.
*Median (IQR).
DDS, Diabetes Distress Scale; HbA1c, hemoglobin A1c (average blood glucose over 12 weeks); logMAR, logarithm of the minimum angle of resolution; PHQ-9, Patient Health Questionnaire 9;
SDSCA, Summary of Diabetes Self-Care Activities.
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reduction on the PHQ-9 from baseline relative to −0.3
±4.6 in the control group (p=0.04). For diabetes self-
care, no signiﬁcant between-group differences in change
scores were found at 3 or 6 months, although a trend
for increased frequency in self-monitoring of blood
glucose in the PST-D group relative to the control group
at 6 months was identiﬁed (PST_D: 1.2±2.7; control:
−0.3±2.5; p=0.09). At 6 months, there was a signiﬁcant
between-group difference in change in HbA1c from
baseline representing a reduction in the intervention
group (−1.2%±1.01) with no change in the control
group (0.2%±1.2%) (p=0.002).
Multivariate analysis, adjusting for baseline values,
sociodemographic, and clinical factors (age, gender,
duration of diabetes, diabetes medication, visual acuity
at baseline), identiﬁed a signiﬁcant impact of PST-D on
‘regimen-related distress’, HbA1c, and depressive symp-
toms at the 6-month visit (p<0.05; table 2).
CONCLUSIONS
This is the ﬁrst pilot randomized controlled trial to
examine the effectiveness of a diabetes-speciﬁc
problem-solving intervention in adults with DR, experi-
encing at least moderate diabetes distress. Our ﬁndings
provide preliminary evidence that this intervention may
improve diabetes distress, particularly associated with the
diabetes regimen. Furthermore, our results suggest that
PST-D has the potential to improve depressive symptoms
and produce a clinically signiﬁcant reduction in HbA1c
of −1.2%. These are important data as few interventions
for people with diabetes have been able to improve psy-
chological and clinical outcomes.16 Targeting this inter-
vention to individuals with early-stage DR and distress
may also offer longer term outcomes, given that
improved glycemic control in this group may delay the
progression of NPDR to the vision-threatening stage.17 A
beneﬁt of the diabetes-speciﬁc PST is that it is designed
to be delivered by diabetes or primary care clinicians,
rather than by mental health specialists. Therefore, with
brief training, existing members of the diabetes or
primary care team could deliver this intervention. In
addition, PST-D could be delivered in accessible formats,
including telephone or online.
Consistent with emerging evidence, our study suggests
that addressing the distress associated with diabetes man-
agement may impact on wider outcomes, such as depres-
sive symptoms and glycemic control. For example, the
REDEEM trial showed that reductions in ‘regimen-
related distress’ were associated with improved diabetes
self-management and glycemic control.18 However, we
found no signiﬁcant effect on self-management beha-
viors, that is, diet and exercise as assessed by the SDSCA.
One explanation is that the SDSCA may not have been
sufﬁciently responsive to the PST-D intervention.
Notably, we did not assess diabetes medication taking
behaviors, which may have impacted on glycemic
control. Hence, the mechanisms underlying change in
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HbA1c, which may be due to a range of neuroendocrine,
inﬂammatory, or behavioral pathways, require further
exploration in a fully powered study. In addition, only
the ‘regimen-related distress’ subscale of the DDS
showed a signiﬁcant change. This may be due to the
study’s lack of power. Post hoc power estimations
revealed this study has sufﬁcient power to detect differ-
ences as a result of the intervention on HbA1c, but
lower power for the PHQ-9 and DDS. Our ﬁndings may
also reﬂect poor precision of the DDS total score and
other subscales, as indicated by our recent Rasch analysis
of the DDS.19 A fully powered study with a psychometric-
ally sound assessment of diabetes distress is required to
conﬁrm these ﬁndings.
Our pilot study was limited by a small sample size
and was potentially underpowered. All participants were
retained in the control group, and engagement in
PST-D was high; however, attrition in the intervention
group attendance at follow-up assessments was lower
(76% and 71% attending for assessments at 3 and 6
months). While this is concerning, attrition in the
range of 20–30% is considered acceptable in behavioral
studies of this nature.20 Loss to follow-up may have
been due to the burden of participation, or it may rep-
resent a self-selection bias skewing results. Indeed, we
found that those who dropped out had lower levels of
regimen-related distress at baseline. This may suggest
that those with lower regimen-related distress may need
less intensive intervention. That those who dropped out
showed a trend to be living alone may indicate the
importance of social support in the uptake of such
interventions and may point to the need for alternative
delivery options (eg, group-based programs). This
requires further examination in future studies. A quali-
tative study would worthwhile to explore reasons for
attrition as well as the applicability and utility of the
PST-D in participants’ daily lives. Our sample also
included a higher proportion of men than women,
which is unusual and may indicate recruitment bias,
given that previous research has indicated higher levels
of diabetes distress in women.21 Research has also indi-
cated that gender differences in the association
between diabetes distress and health behaviors (eg,
physical activity, smoking)21 which requires investigation
in a full-scaled study. Finally, our study included a
‘usual care’ control group rather than an active
(support/attention) condition controlling for non-
speciﬁc intervention effects.
In conclusion, these preliminary ﬁndings suggest the
potential of PST-D, but a fully powered study is
needed to: (1) conﬁrm these ﬁndings, (2) test the
causal mechanisms underlying change in HbA1c taking
into account gender differences; (3) determine longer
term impact on psychological, diabetes, and DR out-
comes; (4) examine the cost-effectiveness of this
approach; and (5) explore the practical issues regard-
ing implementation as an integrated component of
diabetes services.
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